Sangamo Therapeutics, Inc
ST-506
prion disease
Date
TBD
Phase 1 readout · Date TBD estimated
What's at stake
Phase 1 trial results for ST-506 in prion disease are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Clinical Trial Application (CTA) enabling activities are in progress for ST-506, an investigational epigenetic regulator for the treatment of prion disease, leveraging STAC-BBB, Sangamo’s novel proprietary neurotropic adeno-associated virus”